ChemicalBook > CAS DataBase List > Atinumab
Atinumab
- Product Name
- Atinumab
- CAS No.
- 1226761-65-4
- Chemical Name
- Atinumab
- Synonyms
- Atinumab;Atinumab (anti-NOGO);Research Grade Atinumab;Research Grade Atinumab (DHK06702)
- CBNumber
- CB38080823
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Atinumab Chemical Properties,Usage,Production
Uses
Atinumab (NG-101) is a CHO-expressed human antibody that targets RTN4/NOGO. Atinumab (NG-101) carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.62 kDa. The isotype control for Atinumab (NG-101) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Atinumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Atinumab Suppliers
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 12952
- Advantage
- 65
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
1226761-65-4, AtinumabRelated Search:
Quilizumab
Volagidemab
Anselamimab
Ubamatamab
Geptanolimab
Felvizumab
Lanadelumab
Crovalimab
Avdoralimab
Gatipotuzumab